New York Stem Cell干细胞 Foundation (NYSCF)-Druckenmiller Fellow, Daylon James, PhD, of Weill Cornell Medial College, is lead author on a study defining conditions for generating a plentiful supply of endothelial内皮的 (vessel lining) cells that are suitable for therapeutic治疗的 use. Dr. James and his colleagues created a human embryonic胚胎的 stem cell (hESC) "reporter" line that can be used to measure endothelial cell production and activity. The study, Expansion and maintenance of human embryonic stem cell–derived endothelial cells by TGFβ inhibition is Id1 dependent, was published in the online edition of Nature Biotechnology on January 17th, 2010, and will also appear in the journal's print edition. In addition to Dr. James, whose work is funded by NYSCF, contributors to the study also included NYSCF-Druckenmiller Fellows, Drs. Gabsang Lee and Marco Seandel.

Using the reporter line, Dr. James and his colleagues were able to monitor the emergence出现，浮现 of endothelial cells in live cultures, and screen for small bioactive生物活性的 molecules that increased their yield. By this method, they were able to indentify a compound that robustly increased the amount of endothelial cells produced. This work establishes a standard methodology for generating functional endothelial cells from hESCs using conditions that are suited to clinical application. These cells can now be routinely and economically produced on scales that make pre-clinical assessment of their efficacy practical in large animal models of vascular血管的 disease.

"We are very proud of Dr. James. These findings bring us closer to having functional endothelial cells available for studying vascular disease," says Susan L. Solomon, NYSCF's founder and CEO.

As advancements in induced pluripotent多能的 stem (iPS) cell technology continue, hESC research like that of Dr. James is essential for the field of stem cell research. Embryonic stem cells are still the gold standard for monitoring pluripotency and differentiation capabilities.

"It is research like this that brings us closer to cures for the major diseases of our time," said Dr. Kevin Eggan, Chief Scientific Officer of NYSCF. "Daylon is one of the premier第一的，最初的 young scientists in the field of stem cell research and we are excited to have him in our fellowship program."